

## Characteristics of A<sub>1</sub> and A<sub>2</sub> Adenosine Receptors upon the Acetylcholine Release in the Rat Hippocampus

Do Kyung Kim, Young Soo Lee, and Bong Kyu Choi

Department of Pharmacology, Wonkwang University School of Medicine and Medicinal Resources Research Center of Wonkwang University, Iksan 570–749, Korea

As it has been reported that the depolarization induced acetylcholine (ACh) release is modulated by activation of presynaptic A<sub>1</sub> adenosine heteroreceptor and various lines of evidence suggest the A<sub>2</sub> adenosine receptor is present in the hippocampus. The present study was undertaken to delineate the role of adenosine receptors on the hippocampal ACh release. Slices from the rat hippocampus were equilibrated with [<sup>3</sup>H]choline and then the release amount of the labelled product, [<sup>3</sup>H]ACh, which was evoked by electrical stimulation (rectangular pulses, 3 Hz, 2 ms, 24 mA, 5 V/cm<sup>-1</sup>, 2 min), was measured, and the influence of various adenosine receptor-related agents on the evoked tritium outflow was investigated. And also, the drug-receptor binding assay was performed in order to confirm the presence of A<sub>1</sub> and A<sub>2</sub> adenosine receptors in the rat hippocampus. N-ethylcarboxamidoadenosine (NECA), a potent adenosine receptor agonist with nearly equal affinity at A<sub>1</sub> and A<sub>2</sub> adenosine receptors, in concentrations ranging from 1~30 μM, decreased the electrically-evoked [<sup>3</sup>H]ACh release in a concentration-dependent manner without affecting the basal rate of release. And the effect of NECA was significantly inhibited by 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 2 μM), a selective A<sub>1</sub> adenosine receptor antagonist, but was not influenced by 3,7-dimethyl-1-propargylxanthine (DMPX, 5 μM), a specific A<sub>2</sub> adenosine receptor antagonist. N<sup>6</sup>-cyclopentyladenosine (CPA), a selective A<sub>1</sub> adenosine receptor agonist, in doses ranging from 0.1 to 10 μM, reduced evoked [<sup>3</sup>H]ACh release in a dose-dependent manner without the change of the basal release. And the effect of CPA was significantly inhibited by 2 μM DPCPX treatment. 2-P-(2-carboxyethyl)-phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride (CGS-21680C), a potent A<sub>2</sub> adenosine receptor agonist, in concentrations ranging from 0.1 to 10 μM, did not alter the evoked ACh release. In the drug-receptor binding assay, the binding of [<sup>3</sup>H]2-chloro-N<sup>6</sup>-cyclopentyladenosine ([<sup>3</sup>H]CCPA) to the A<sub>1</sub> adenosine receptor of rat hippocampal membranes was inhibited by CPA (K<sub>i</sub> = 1.22 nM), NECA (K<sub>i</sub>=10.17 nM) and DPCPX (K<sub>i</sub>=161.86 nM), but not by CGS-21680C (K<sub>i</sub>=2,380 nM) and DMPX (K<sub>i</sub>=22,367 nM). However, the specific binding of [<sup>3</sup>H]CGS-21680C to the A<sub>2</sub> adenosine receptor was not observed. These results suggest that the A<sub>1</sub> adenosine heteroreceptor play an important role in evoked ACh release, but the presence of A<sub>2</sub> adenosine receptor is not confirmed in this study.

Key Words: Adenosine receptors, Acetylcholine, Hippocampus, Drug-receptor binding assay

### INTRODUCTION

It is well known that adenosine and its analogues inhibit the release of several neurotransmitters in the

central nervous system (CNS). Adenosine receptors are subdivided into A<sub>1</sub> and A<sub>2</sub> adenosine receptors for their ability to either inhibit or stimulate adenylate cyclase (Daly et al, 1983; Hamprecht and Van Calker, 1985). The inhibition by adenosine analogues of several neurotransmitters including ACh, norepinephrine, 5-hydroxytryptamine and glutamate is apparently mediated via A<sub>1</sub> adenosine receptors (Jac kisch et al, 1985; Fredholm et al, 1986; Fredholm and

Corresponding to: Do Kyung Kim, Department of Pharmacology, Wonkwang University School of Medicine and Medicinal Resources Research Center of Wonkwang University, Iksan 570–749, Korea

Lindgren, 1987). In the hippocampus, the release of ACh could be inhibited both by presynaptic muscarinic receptor (Hertting et al, 1987; Choi et al, 1991) and by presynaptic A<sub>1</sub> adenosine receptor (Jaksch et al, 1984; Choi et al, 1992).

On the other hand, the A<sub>2</sub> adenosine receptor existed in the CNS as well as in the peripheral organs such as heart (Stone et al, 1988; Williams, 1989; Bruns, 1990). However, there have been still controversy about existence of A<sub>2</sub> adenosine receptor in the hippocampus. Fredholm (1982) and Fredholm et al. (1983) showed that A<sub>1</sub> and A<sub>2</sub> adenosine receptors in the hippocampal tissue decreased cAMP concentration and increased it, respectively. Sebastião and Ribeiro (1992) reported that 2-p-(2-carboxyethyl) phenethylamino-5'-N-ethylcarboxamidoadenosine hydrochloride (CGS-21680C), a specific A<sub>2</sub> adenosine receptor agonist, increased excitability of the hippocampus in an electrophysiological study. Lee (1994) and Cunha et al (1995) suggested a possible existence of the excitatory effect of A<sub>2</sub> adenosine receptor in rat hippocampal neurons. On the contrary, Yeung and Green (1984) reported that only A<sub>1</sub> subtype was demonstrated in the hippocampus by the experiment with the rat hippocampal homogenate. And Jarvis and his colleagues (1989) assumed that both A<sub>1</sub> and A<sub>2</sub> adenosine receptors existed in the striatum but only A<sub>1</sub> adenosine receptor existed in the hippocampus. Therefore, the functional role of A<sub>1</sub> and A<sub>2</sub> adenosine receptors in many organs has been known well whereas the anatomical evidence and physiological role of adenosine receptor subtypes have not been clear in the hippocampus.

The purpose of this study was to compare the role of the A<sub>1</sub> and A<sub>2</sub> adenosine receptors for the electrical stimulation-induced ACh release and to examine the existence of the A<sub>1</sub> and A<sub>2</sub> adenosine receptors using the drug-receptor binding assay in the rat hippocampus.

## METHODS

### *Superfusion experiments*

Slices of 2.5~3.0 mg, 400  $\mu$ m in thickness, were prepared from the hippocampus of Sprague-Dawley rats weighing 250~300 gm with a Balzers<sup>®</sup> tissue chopper (Balzers Union Aktiengesellschaft, England) and were incubated in 2 ml of modified Krebs-

Henseleit medium containing 0.1  $\mu$ mol/L [<sup>3</sup>H]choline for 30 min at 37°C. Subsequently, the [<sup>3</sup>H]choline-pretreated slices were superfused with medium containing hemicholinium-3 (10  $\mu$ M) and atropine (30 nM) for 140 min at a rate of 0.5 ml/min. The composition (mM) of superfusion medium was 118 NaCl, 4.8 KCl, 2.5 CaCl<sub>2</sub>, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 1.2 MgSO<sub>4</sub>, 25 NaHCO<sub>3</sub>, 0.57 ascorbic acid, 0.03 Na<sub>2</sub>EDTA and 11 glucose, and the superfusate was continuously aerated with 95% O<sub>2</sub>+5% CO<sub>2</sub>; the pH adjusted to 7.4.

Collection of 5 min fraction of the superfusate began after 50 min of superfusion. Electrical stimulations (3 Hz, 5 Vcm<sup>-1</sup>, 2 ms, rectangular pulses) for 2 minutes were performed at 60 min (S<sub>1</sub>) and 120 min (S<sub>2</sub>). Drugs were added between S<sub>1</sub> and S<sub>2</sub> to the superfusion medium. At the end of superfusion, the slices were solubilized in 0.5 ml tissue solubilizer (0.5 N quaternary ammonium hydroxide in toluene). The radioactivities in the superfusates and solubilized tissues were determined by liquid scintillation counting (Beckman LS 6500TD). The fractional rate of tritium-outflow (5 min<sup>-1</sup>) was calculated as tritium-outflow per 5 min divided by the total tritium content in the slice at the start of the respective 5 min period (Hertting et al, 1980). As reported previously, the electrical stimulation of brain slices incubated with [<sup>3</sup>H]choline causes the release of [<sup>3</sup>H]ACh only (Richardson & Szerb, 1974). Drug effects on the evoked tritium-outflows were evaluated by calculating the ratio of the outflow evoked by S<sub>2</sub> and by S<sub>1</sub> (S<sub>2</sub>/S<sub>1</sub>). The influence of drugs on the basal outflow are expressed as the ratio b<sub>2</sub>/b<sub>1</sub> between fractional rates of outflow immediately before S<sub>2</sub> (115~120 min) and S<sub>1</sub> (55~60 min).

The following chemicals were used: [methyl-<sup>3</sup>H] choline chloride (72~78 Ci mmol<sup>-1</sup>, Amersham), N-ethylcarboxamidoadenosine (NECA, Sigma), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, RBI), atropine sulfate (Sigma), CGS-21680C (RBI), N<sup>6</sup>-cyclopentyladenosine (CPA, RBI), hemicholinium-3 (Sigma), 3,7-dimethyl-1-propargylxanthine (DMPX, RBI). Drugs were dissolved in the medium except for DPCPX which were initially dissolved in DMSO and then diluted in the medium. The maximum concentration of DMSO used in the experiments (0.1%, vol/vol) did not affect basal tritium outflow or stimulation-evoked [<sup>3</sup>H]ACh release.

### Receptor binding assay

Rats were sacrificed by decapitation, and their brains rapidly removed to ice. The hippocampus was dissected from the remaining brain tissue, collected in Tris-buffer (50 mM Tris HCl, 10 mM MgCl<sub>2</sub>, pH adjusted to 7.4) and chilled on ice. The tissues were homogenized in 10 volumes of Tris-buffer with up and down stroke of a motor driven glass-teflon homogenizer on ice. The hippocampal homogenate was filtered through two layers of gauze and the filtrate centrifuged at 40,000 × g for 10 min at 4°C. The resulting pellet was resuspended in 10 volumes of ice-cold buffer and stirred for 30 min at 4°C. After the homogenate was recentrifuged at 40,000 × g for 10 min at 4°C, the pellet was resuspended in 20 volumes of Tris-buffer. Adenosine deaminase (2 IU/ml) was added and the suspension was incubated at 37°C for 30 min to remove endogenous adenosine. The suspension was recentrifuged at 40,000 × g for 10 min at 4°C and the final pellet was resuspended in ice-cold Tris-buffer. The crude membranes were stored frozen at -70°C. Protein contents were determined by the method of Bradford (1976) using bovine serum albumin as a standard.

Membranes were thawed at room temperature and homogenized by 10 strokes in a glass-teflon homogenizer. For A<sub>1</sub> adenosine receptor assays, DMPX (3 μM) was added to each tube in order to block A<sub>2</sub> adenosine sites and for A<sub>2</sub> adenosine receptor assays, DPCPX (2 μM) was added to each tube in order to block A<sub>1</sub> adenosine sites. These concentrations of site selective displacing ligands were selected from an analysis of their potencies as displacers of each labeled ligand. After all additions, the final membrane concentration in the assay tube was 1% w/v, corresponding to about 300~500 μg protein per sample. All drug solutions were prepared in Tris-buffer, pH 7.4. Final volume in each tube was 500 μl. Triplicate samples of membrane suspension were preincubated with or without non-radioactive displacer at 25°C. Radiolabelled ligands, 1 nM [<sup>3</sup>H]2-chloro-N<sup>6</sup>-cyclopentyladenosine ([<sup>3</sup>H]CCPA) or 16 nM [<sup>3</sup>H]CGS-21680C, were then added and the incubation continued for 120 min at the same conditions. The incubation was terminated by addition of 4 ml ice-cold buffer and rapid filtration through glass fiber filters (Type G-7; Inotech, Zürich, Switzerland) under reduced pressure by using a cell harvester (Inotech). The filters were washed with additional 4 ml buffer,


transferred to scintillation vials, soaked in 0.5 ml absolute ethanol, and counted in 3 ml scintillation cocktail by liquid scintillation counter (Beckman LS 6500TD). Non-specific binding was defined as the fraction of bound radioligand that remained in the presence of 20 μM NECA.

Saturation and displacement data were analyzed by the use of the computer program LIGAND (Munson and Rodbard, 1980). This program utilizes a non-linear least squares curve fitting algorithm, and assumes the simultaneous contribution of one or more independent binding sites.

The following chemicals were used: [<sup>3</sup>H]CCPA (30~60 Ci mmol<sup>-1</sup>, Dupont New England Nuclear), [<sup>3</sup>H]CGS-21680C (30~80 Ci mmol<sup>-1</sup>, Dupont New England Nuclear), adenosine deaminase (Type VI, Sigma).

### Statistics

All results are given as Mean ± SEM. Significance of difference between the groups was determined by ANOVA and subsequently by Duncan test (Snedecor, 1980).



**Fig. 1.** A typical presentation of the tritium-outflow from the rat hippocampal slice preincubated with [<sup>3</sup>H]choline. The slices were electrically stimulated twice for 2 min after 60 (S<sub>1</sub>) and 120 min (S<sub>2</sub>) of superfusion, respectively. The drug effect on the stimulation-evoked tritium outflow is expressed by the ratio S<sub>2</sub>/S<sub>1</sub>. N-ethylcarboxamidoadenosine (NECA) and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) were added 15 min before S<sub>2</sub>. The tritium contents of the tissue at the start of experiments were 0.755 ± 0.009 (○) and 0.810 ± 0.046 (●) pmol. The mean ± SEM of the experiments (n) are given. Asterisks indicate the significant difference between groups (\*\*; p < 0.01).

## RESULTS

### Effects of adenosine receptor agonists and antagonists on [<sup>3</sup>H]ACh release


Hippocampal slices prelabelled with [<sup>3</sup>H]choline, a [<sup>3</sup>H]ACh precursor, were superfused with the medium containing hemicholinium-3 (10 μM), a choline uptake inhibitor. And in order to eliminate the inhibition of ACh release by activating muscarinic autoreceptor, atropine (30 nM) was added in the superfusion medium. During superfusion, the tissues were electrically stimulated twice.

As shown in Fig. 1, the example of the experiment observed the influence of NECA, a potent adenosine receptor agonist with nearly equal affinity at A<sub>1</sub> and A<sub>2</sub> adenosine receptors (Jackish et al, 1984), on [<sup>3</sup>H]ACh release. NECA, in doses ranging from 1 to 30 μM, decreased the electrically-evoked [<sup>3</sup>H]ACh release in a concentration-dependent manner (Table 1).

To ascertain the interaction between NECA and DPCPX, a selective A<sub>1</sub> adenosine receptor antagonist (Bruns et al, 1987), or DMPX, a selective A<sub>2</sub> adenosine receptor antagonist (Sebastião and Ribeiro, 1989), the effect of NECA was observed in the presence of the 2 μM DPCPX (control:  $b_2/b_1 = 0.6394 \pm 0.0273$ ,  $S_2/S_1 = 1.0054 \pm 0.0215$ ,  $n=7$ , 2 μM DPCPX:  $b_2/b_1 = 0.6605 \pm 0.0155$ ,  $S_2/S_1 = 1.0351 \pm 0.0746$ ,  $n=8$ ) or 5 μM DMPX (control:  $b_2/b_1 = 0.6101 \pm 0.0293$ ,  $S_2/S_1 = 0.9417 \pm 0.0447$ ,  $n=5$ , 5 μM DMPX:  $b_2/b_1 = 0.6715 \pm 0.0239$ ,  $S_2/S_1 = 0.8223 \pm 0.0751$ ,  $n=6$ ). All

drugs were added to the superfusion medium 15 min before S<sub>2</sub>. The decrements of tritium outflow by NECA were significantly inhibited by DPCPX (Fig. 2), but were not influenced by DMPX (Fig. 3).

CPA, a selective A<sub>1</sub> adenosine receptor agonist (Williams et al, 1986), in doses ranging from 0.1 to 10 μM, decreased the electrically-evoked [<sup>3</sup>H]ACh release in a dose-dependent manner without change of the basal release (Fig. 4). In addition, the effect of CPA was significantly inhibited by 2 μM DPCPX




**Fig. 2.** Influence of DPCPX on the effect of NECA on the electrically-evoked tritium outflow from the rat hippocampus. In parentheses are the number of experiments. Asterisks indicate the significant difference between groups (\*;  $p < 0.05$ ). Other legends are the same as in Fig. 1.


**Table 1.** Effect of N-ethylcarboxamidoadenosine (NECA) on the electrically-evoked and basal outflow of tritium from the rat hippocampal slices preincubated with [<sup>3</sup>H]choline

	Drugs at S <sub>2</sub> (μM)	n	S <sub>2</sub> /S <sub>1</sub>	b <sub>2</sub> /b <sub>1</sub>
NECA	none	12	0.9789 ± 0.0232	0.6272 ± 0.0197
	1	4	0.7516 ± 0.1057	0.6684 ± 0.0241
	3	8	0.7073 ± 0.0341***	0.5862 ± 0.0224
	10	8	0.6036 ± 0.0281***	0.6114 ± 0.0177
	30	3	0.3650 ± 0.0266***	0.5396 ± 0.0109**


After preincubation, the slices were superfused with medium containing hemicholinium-3 (10 μM) and atropine (30 nM), and then stimulated twice (S<sub>1</sub>, S<sub>2</sub>). Drugs were present from 15 min before S<sub>2</sub> onwards at the concentrations indicated. Drug effects on basal outflow are expressed at the ratio  $b_2/b_1$  between fractional rates of outflow immediately before S<sub>2</sub> (95 min ~ 100 min) and before S<sub>1</sub> (55 min ~ 60 min). Mean ± SEMs from number (n) of observations are given. Significant differences from the drug-free control (none) are marked with asterisks (\*\*;  $p < 0.01$  and \*\*\*;  $p < 0.001$ ).



**Fig. 3.** Influence of 3,7-dimethyl-1-propargylxanthine (DMPX) on the effect of NECA on the electrically-evoked tritium outflow from the rat hippocampus. Legends are the same as in Fig. 2.



**Fig. 5.** Influence of DPCPX on the effect of CPA on the electrically-evoked tritium outflow from the rat hippocampus. Legends are the same as in Fig. 4.



**Fig. 4.** Effects of N<sup>6</sup>-cyclopentyladenosine (CPA) and 2-p-(2-carboxyethyl)phenethylamino- 5'-N-ethylcarboxamidoadenosine hydrochloride (CGS-21680C) on the electrically-evoked outflow of tritium from the rat hippocampal slices preincubated with [<sup>3</sup>H]choline. Drugs were present from 15 min before S<sub>2</sub> onwards at the concentrations indicated. Each point denotes mean ± SEM. In parentheses are the number of experiments. Significant differences from the drug-free control (0 μM) are marked with asterisks (\*\*\*; p < 0.001). Other legends are the same as in Fig. 2.

(Fig. 5).

In order to study the role of A<sub>2</sub> adenosine receptor on ACh release in the rat hippocampus, the effect of CGS-21680C, an adenosine agonist which possesses a 170 fold selectivity for A<sub>2</sub> versus A<sub>1</sub> adenosine receptor (Hutchison et al, 1989), was examined. As

shown in Fig. 4, CGS-21680C did not influence the electrically-evoked [<sup>3</sup>H]ACh release and basal release. On the other hand, as it was thought that if the stimuli of A<sub>1</sub> adenosine receptor had blocked the effect of A<sub>2</sub> adenosine receptor could have appeared, the effect of CGS-21680C observed in the presence of DPCPX, but CGS-21680C in the presence of the 2 μM DPCPX did not influence the ACh release (Table 2).

#### Receptor binding experiments


In the drug-receptor binding experiment with hippocampal membranes, after incubation for 120 min at 25°C, [<sup>3</sup>H]CCPA (1 nM) was bound with specific binding amount approximately 85 % of total binding. However, the specific binding of [<sup>3</sup>H]CGS-21680C (16 nM) was not detected.

In rat hippocampal membrane preparation, when A<sub>2</sub> adenosine receptors were blocked by 3 μM DMPX, [<sup>3</sup>H]CCPA binding was inhibited by CPA with a K<sub>i</sub> value of 1.22 nM and a B<sub>max</sub> of 219 fmol/mg protein (Fig. 6, Table 3). Also, competitions by several agonists and antagonists for [<sup>3</sup>H]CCPA binding were measured to confirm the [<sup>3</sup>H]CCPA binding to A<sub>1</sub> adenosine receptors. The specific binding of [<sup>3</sup>H]CCPA was inhibited by CPA, NECA and DPCPX, the A<sub>1</sub> adenosine receptor-related drugs, but not by CGS-21680C and DMPX, the A<sub>2</sub> adenosine receptor-related drugs (Fig. 6, Table 3).

**Table 2.** Influence of 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) upon the effect of 2-p-(2-carboxyethyl) phenethyl-amino-5'-N-ethylcarboxamidoadenosine hydrochloride (CGS-21680C) on the electrically-evoked tritium-outflows from the rat hippocampus

Drugs at S <sub>2</sub> (μM)		n	S <sub>2</sub> /S <sub>1</sub>	Net inhibition by CGS-21680C (%)
DPCPX	CGS-21680C			
—	—	13	1.067 ± 0.019	
2	—	4	1.174 ± 0.072	
—	0.1	4	1.052 ± 0.053	— 0.015 (−1.4)
2	0.1	4	1.042 ± 0.060	— 0.132 (−11.2)
—	0.3	4	1.096 ± 0.089	+ 0.029 (+ 2.7)
2	0.3	4	1.294 ± 0.060	+ 0.120 (+10.2)
—	1	4	1.101 ± 0.015	+ 0.034 (+ 3.2)
2	1	4	1.112 ± 0.031	— 0.062 (−5.3)
—	3	4	1.163 ± 0.086	+ 0.096 (+ 9.0)
2	3	4	1.166 ± 0.063	— 0.008 (−0.7)

Legends are the same as in Table 1.



**Fig. 6.** Comparison of inhibitory potency of CPA, NECA, DPCPX, CGS-21680C and DMPX on the [<sup>3</sup>H]2-chloro-N<sup>6</sup>-cyclopentyladenosine ([<sup>3</sup>H]CCPA) binding in the presence of 3 μM DMPX as a blocking ligands for A<sub>2</sub> adenosine receptors in the rat hippocampal membranes.

## DISCUSSION

In the present study, the electrically-evoked ACh release from the rat hippocampal slice was inhibited by NECA, a adenosine receptor agonist with nearly equal affinity at A<sub>1</sub> and A<sub>2</sub> adenosine receptor and CPA, a selective A<sub>1</sub> adenosine receptor agonist. And the inhibitory effects of CPA were far greater than those of NECA. This result is in accordance with other reports that CPA is more potent than NECA in

**Table 3.** Affinity constant (K<sub>i</sub>, nM) of various adenosine receptor agonists and antagonists for specific binding site of [<sup>3</sup>H]chloro-N<sup>6</sup>-cyclopentyladenosine ([<sup>3</sup>H]CCPA) in the presence of blocking ligands for A<sub>2</sub> adenosine site in the rat hippocampal membranes

Compound	K <sub>i</sub> (nM)
CPA	1.22
NECA	10.17
DPCPX	161.86
CGS-21680C	2,380
DMPX	22,367

K<sub>i</sub> Values were derived by the computer program LIGAND. Each value represented the mean of two or more independent experiment with varying SEMs less than ±10%. All experiments were carried out using Tris-buffer (50 mM Tris HCl, 10 mM MgCl<sub>2</sub>, pH adjusted to 7.4). CPA: N<sup>6</sup>-cyclopentyladenosine, NECA: N-ethylcarboxamidoadenosine, DPCPX: 8-cyclopentyl-1, 3-dipropylxanthine, CGS-21680C: 2-p-(2-carboxyethyl) phenethylamino-5'-N- ethylcarboxamidoadenosine hydrochloride, DMPX: 3,7-dimethyl-1-propargylxanthine.

ACh release experiment by using the hippocampal tissue (Londos et al, 1980; Jackish et al, 1984; Moos et al, 1985; Fredholm, 1990). Moreover, the decreasing effect of ACh release by CPA or NECA was completely antagonized by DPCPX, a selective A<sub>1</sub> adenosine receptor antagonist, in this study. As these

results correspond to the reports about the inhibition of ACh release by CPA (Dunér-Engström & Fredholm, 1988; Choi et al, 1992) or NECA (Jackish et al, 1984; Fredholm., 1990), it is suggested that the effects of CPA and NECA were mediated by A<sub>1</sub> adenosine receptor subtype.

Since it was known that the existence of A<sub>2</sub> adenosine receptor in the CNS, a large body of experimental evidences about the existence of A<sub>2</sub> adenosine receptor in the hippocampus have been accumulated. Sebastião and Ribeiro (1992) observed that CGS-21680C, a selective A<sub>2</sub> adenosine receptor agonist, increased the electrophysiological excitability of the rat hippocampal slices. Cunha et al (1995) reported that CGS-21680C increased the veratridine-induced ACh release in the experiments on the neurotransmitter release from the rat hippocampal homogenate, and they insisted the existence of A<sub>2</sub> adenosine receptor in the hippocampus. And, Bartrup and Stone (1988) observed that when the A<sub>1</sub> adenosine receptor was blocked, the effect of A<sub>2</sub> adenosine receptor could be expressed. In addition, Lee (1994) reported that when Mg<sup>++</sup> was removed from the superfusion medium and then the inhibitory effect of A<sub>1</sub> adenosine receptor disappeared, the excitatory effect of A<sub>2</sub> adenosine receptor could be expressed, and also, we reported previously that the excitatory effect of A<sub>2</sub> adenosine receptor on neurotransmitter release from the rat hippocampus appeared when Mg<sup>++</sup> was removed from the superfusion medium (Park et al, 1997). However, Yeung and Green (1984) described that both A<sub>1</sub> and A<sub>2</sub> adenosine receptors were present and functionally relevant in the rat striatum whereas only A<sub>1</sub> adenosine receptor was present in the rat hippocampus. Therefore, in this study, it was attempted to clarify whether A<sub>2</sub> adenosine receptor is involved in the evoked ACh release in the rat hippocampus. NECA decreased the electrically-evoked ACh release, and the inhibitory effect of NECA was antagonized by DPCPX but were not altered by DMPX, a selective A<sub>2</sub> adenosine receptor antagonist. Furthermore, CGS-21680C which has about 170 fold selectivity for A<sub>2</sub> versus A<sub>1</sub> adenosine receptor did not influence on the electrically-evoked ACh release at all. Even in the presence of DPCPX, CGS-21680C did not alter the basal and evoked rates of ACh release. These findings, in conjunction with other report (Yeung & Green, 1984) that only A<sub>1</sub> adenosine receptor was present in the rat hippocampus, suggests that the A<sub>1</sub>

adenosine receptor subtype can be related to the functional role of the cholinergic nerve terminal on the ACh release in the rat hippocampus.

Recently, Cunha et al (1995) observed the expression of A<sub>2A</sub> mRNA in in situ hybridization in coronal rat brain section, and they proposed that A<sub>2A</sub> adenosine receptors could be present in hippocampal cholinergic nerve terminals. Therefore, in this study, the drug-receptor binding assay using [<sup>3</sup>H]CCPA and [<sup>3</sup>H]CGS-21680C was performed in order to clarify the existence of A<sub>1</sub> and A<sub>2</sub> adenosine receptors and to examine the ligand selectivity of A<sub>1</sub> and A<sub>2</sub> adenosine receptors in rat hippocampal membranes. The specific binding of [<sup>3</sup>H]CCPA was more than 85 % of total binding rate but the specific binding of [<sup>3</sup>H]CGS-21680C was not observed. On the other hand, the binding of [<sup>3</sup>H]CCPA was blocked by CPA, NECA and DPCPX, but was not blocked by CGS-21680C and DMPX. Also, in our previous study using the buffer (including Mg<sup>2+</sup> or not), the specific binding of [<sup>3</sup>H]CGS-21680C to rat hippocampus was revealed not to be significant (Kim et al, 1997). These results were consistent with the report of Yeung and Green (1984) from the drug-receptor binding experiment, suggesting that the functionally relevant A<sub>2</sub> adenosine receptors are not exist in the rat hippocampus. However, our result and the results of others (Bartrup & Stone, 1988; Sebastião & Ribeiro, 1992; Lee, 1994; Cunha et al, 1995) about the presence and the role of A<sub>2</sub> adenosine receptor in hippocampal tissue are substantially inconsistent. The apparent discrepancy between the present result and the previous reports may be ascribed to the differences of experimental methods used, i.e. the hippocampal slices and synaptosomes, the drug-receptor binding assay and the in situ hybridization, the neurotransmitter release experiments and the electrophysiological experiments. Hence, further studies are required to understand the presence and the role of A<sub>2</sub> adenosine receptor in the rat hippocampus.

Overall, the results of the present study suggests that the decrement of the evoked ACh release is mediated by A<sub>1</sub> adenosine heteroreceptor in the rat hippocampal cholinergic neurons, and that the A<sub>2</sub> adenosine receptor seems not to exist in the rat hippocampus.

#### ACKNOWLEDGEMENT

This paper was supported by Wonkwang Univer-

sity in 1997.

## REFERENCES

- Bartrup JT, Stone TW. Interactions of adenosine and magnesium on rat hippocampal slices. *Brain Res* 463: 374–379, 1988
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. *Anal Biochem* 72: 248–254, 1976
- Bruns RF, Fergus JH, Badger EW, Bristol JA, Santay LA, Hartman JD, Hays SJ, Huang CC. Binding of the A<sub>1</sub>-selective adenosine antagonist 8-cyclopentyl-1, 3-dipropylxanthine to rat brain membranes. *Naunyn-Schmiedeberg's Arch Pharmacol* 335: 59–63, 1987
- Bruns RF. Structure activity relationships for adenosine antagonists. In: Purines in cellular signalling: Targets for New Drugs (Jacobson, KA, Daly, JW and Mangiello, V., eds.), New York Springer-Verlag p126–135, 1990
- Choi BK, Kim CS, Yoon YB, Kook YJ. Interaction of forskolin with the effect of oxotremorine on [<sup>3</sup>H] acetylcholine release in rabbit hippocampus. *Korean J Pharmacol* 27: 89–97, 1991
- Choi BK, Park HM, Kang YW, Kook YJ. Interaction of forskolin with the effect of N<sup>6</sup>-cyclopentyladenosine on [<sup>3</sup>H]acetylcholine release in rat hippocampus. *Korean J Pharmacol* 28: 129–136, 1992
- Cunha RA, Johansson B, Fredholm BB, Ribeiro A, Sebastião AM. Adenosine A<sub>2A</sub> receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. *Neurosci Lett* 196: 41–44, 1995
- Daly JW, Butts-Lamb P, Padgett W. Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines. *Cell Mol Neurobiol* 3: 69–80, 1983
- Dunér-Engström M, Fredholm BB. Evidence that prejunctional adenosine receptors regulating acetylcholine release from rat hippocampal slices are linked to a N-ethylmaleimide-sensitive G-protein, but not to adenylate cyclase or dihydropyridine-sensitive Ca<sup>2+</sup>-channels. *Acta Physiol Scand* 134: 119–126, 1988
- Fredholm BB, Jonzon B, Lindström K. Adenosine receptor mediated increases and decreases in cyclic AMP in hippocampal slices treated with forskolin. *Acta Physiol Scand* 117: 461–463, 1983
- Fredholm BB, Jonzon B, Lindström K. Effect of adenosine receptor agonists and other compounds on cyclic AMP accumulation in forskolin-treated hippocampal slices. *Naunyn-Schmiedeberg's Arch Pharmacol* 332: 173–178, 1986
- Fredholm BB, Lindgren E. Effect of N-ethylmaleimide and forskolin on noradrenaline release from rat hippocampal slices. Evidence that prejunctional adenosine and  $\alpha$ -receptors are linked to N-proteins but not to adenylate cyclase. *Acta Physiol Scand* 130: 95–100, 1987
- Fredholm BB. Adenosine A<sub>1</sub>-receptor-mediated inhibition of evoked acetylcholine release in the rat hippocampus dose not depend on protein kinase C. *Acta Physiol Scand* 140: 245–255, 1990
- Fredholm BB. Adenosine receptors. *Med Biol* 60: 289–293, 1982
- Hamprecht B, Van Calker D. Nomenclature of adenosine receptors. *Trends Pharmacol Sci* 6: 153–154, 1985
- Hertting G, Wuster S, Gebicke-Harter P, Allgaier C. Participation of Regulatory G-proteins and protein kinase C in the modulation of transmitter release in hippocampus. Modulation of synaptic transmission and plasticity in nervous system. *NATO ASI Series* 19: 147–164, 1987
- Hertting G, Zumstein A, Jackisch R, Hoffmann I, Starke K. Modulation by endogenous dopamine of the release of acetylcholine in the caudate nucleus of the rabbit. *Naunyn-Schmiedeberg's Arch Pharmacol* 315: 111–117, 1980
- Hutchison AJ, Webb RL, Oei HH, Ghai GR, Zimmerman MB, Williams M. CGS 21680C, an A<sub>2</sub> selective adenosine receptor agonist with preferential hypotensive activity. *J Pharmacol Exp Ther* 251: 47–55, 1989
- Jackisch R, Fehr R, Hertting G. Adenosine: an endogenous modulator of hippocampal noradrenaline release. *Neuropharmacology* 24: 499–507, 1985
- Jackisch R, Strittmatter H, Kasakov L, Hertting G. Endogenous adenosine as a modulator of hippocampal acetylcholine release. *Naunyn-Schmiedeberg's Arch Pharmacol* 327: 319–325, 1984
- Jarvis MF, Schulz R, Hutchison AJ, Do UH, Sills MA, Williams M. [<sup>3</sup>H]CGS 21680C, a selective A<sub>2</sub> receptors in rat brain. *J Pharmacol Exp Ther* 251: 888–893, 1989
- Kim DK, Kim HA, Choi BK. The role of adenosine receptor in acetylcholine release in the rat striatum. *Korean J Physiol Pharmacol* 1: 1–12, 1997
- Lee KS. *The effect of magnesium on norepinephrine release in the rat hippocampus*. Inaugural Thesis Wonkwang University Graduate School, 1994
- Londos C, Cooper DMF, Wolff J. Subclasses of external adenosine receptor. *Proc Natl Acad Sci USA* 77: 2551–2554, 1980
- Moos WH, Szotek DS, Bruns RF. N<sup>6</sup>-Cycloalkyladenosines. Potent, A<sub>1</sub>-selective adenosine agonists. *J Med Chem* 28: 1383–1384, 1985
- Munson PJ, Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand binding systems. *Anal Biochem* 107: 220–226, 1980



- Park YB, Park SD, Choi BK. The influence of N<sup>6</sup>-cyclopentyladenosine and magnesium on norepinephrine release in the rat hippocampus. *Korean J Physiol Pharmacol* 1: 135–142, 1997
- Richardson IW, Szerb JC. The release of labelled acetylcholine and choline from cerebral cortical slices stimulated electrically. *Brit J Pharmacol* 52: 499–507, 1974
- Sebastião AM, Ribeiro JA. 1,3,8- and 1,3,7-substituted xanthines: relative potency as adenosine receptor antagonists at the frog neuromuscular junction. *Br J Pharmacol* 96: 211–219, 1989
- Sebastião AM, Ribeiro JA. Evidence for presence of excitatory A<sub>2</sub> adenosine receptors in the rat hippocampus. *Neuroscience Lett* 138: 41–44, 1992
- Snedecor GW, Cochran WG. Statistical methods. Iowa State Univ 7th ed, 1980
- Stone GA, Jarvis MF, Sills MS, Weeks B, Snowhill EW, Williams M. Specific difference in high-affinity adenosine A<sub>2</sub> binding sites in striatal membranes from mammalian brain. *Drug Dev Res* 15: 31–46, 1988
- Williams M, Braunwalser A, Erickson TJ. Evaluation of the binding of the A<sub>1</sub>-selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue. *Naunyn-Schmiedeberg's Arch Pharmacol* 332: 179–183, 1986
- Williams M. adenosine: The prototypic neuromodulator. *Neurochem Int* 14: 249–264, 1989
- Yeung S-MH, Green RD. [<sup>3</sup>H]5'-N-ethylcarboxamido-adenosine binds to both R<sub>a</sub> and R<sub>i</sub> adenosine receptors in rat striatum. *Naunyn-Schmiedeberg's Arch Pharmacol* 325: 218–225, 1984
-